Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors

Core Viewpoint - Perspective Therapeutics, Inc. has initiated the treatment of the first patient in the second cohort of its Phase 1/2a trial for the radiopharmaceutical [Pb]PSV359, targeting solid tumors expressing fibroblast activation protein alpha (FAP-α) [1][3] Group 1: Clinical Trial Details - The second cohort of the trial involves patients receiving [Pb]PSV359 at a dose of 5.0 mCi for up to four doses every eight weeks, with a recommendation from the Safety Monitoring Committee to evaluate higher doses based on initial patient responses [2][5] - The primary objective of the trial is to assess the safety and tolerability of various doses of [Pb]PSV359, aiming to determine the recommended Phase 2 dose for further study [5] Group 2: Mechanism and Targeting - [Pb]PSV359 is designed to target tumor sites expressing FAP-α, which is associated with several prevalent solid tumors, providing a potential treatment option for patients with limited alternatives [4][6] - FAP-α is predominantly expressed on cancer-associated fibroblasts in the tumor microenvironment and is linked to poor prognosis in various solid tumors, including pancreatic and colorectal cancers [6] Group 3: Company Overview - Perspective Therapeutics, Inc. specializes in developing radiopharmaceuticals that utilize alpha-emitting isotopes to deliver targeted radiation to cancer cells, enhancing treatment efficacy while minimizing toxicity [7] - The company is also advancing complementary imaging diagnostics that utilize the same targeting moieties, facilitating personalized treatment approaches [7][8]